Early preclinical studies with the PI3K inhibitors Wortmannin [100,101] and LY294002 [102] suggested that the complete inhibition of all PI3K isoforms could provide a positive response to treatments in PIK3CA-mutant cancers. This evidence concerns the gene PIK3CA and cancer.